Richard Schwameis - Gynecology

Author Information

Richard Schwameis is affiliated with the Department of Gynecology and Gynecologic Oncology at Kliniken Essen-Mitte in Essen, Germany. His research focuses primarily on ovarian cancer, a critical area within gynecologic oncology.

Research Contributions

Richard Schwameis has made significant contributions to the field of gynecologic oncology, particularly in ovarian cancer. His recent works include studies on the prognostic value of nutritional status in ovarian cancer patients, the role of hyperthermic intraperitoneal chemotherapy, and the incorporation of patient-centered benefits in randomized trials of maintenance therapies. Schwameis has also explored the roles of various biomarkers, such as factor XIII and PD-1/PD-L1, in predicting clinical outcomes in ovarian cancer. His research extends to real-world data on germline BRCA1/2 mutations and molecular profiling in endometrial cancer, emphasizing a precision medicine approach.

Aliases

R Schwameis, Richard Schwameis

Publication and Citation Metrics

Metric	Value
Total Citation Count	565
h-index	14
Paper Count	61

Publications:

The Pretreatment Controlling Nutritional Status Score in Ovarian Cancer: Influence on Prognosis, Surgical Outcome, and Postoperative Complication Rate

DOI: 10.1055/a-1608-1309

Year: 2022

There is no role for hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer

DOI: 10.1136/ijgc-2022-003348

Year: 2022

Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee.

DOI: 10.1016/j.ygyno.2021.02.018

Year: 2021

The role of factor XIII in surgery for advanced stage of epithelial ovarian cancer

DOI: 10.1007/s00404-021-06308-z

Year: 2021

PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome

DOI: 10.1038/s41598-021-85966-0

Year: 2021

Clinical outcome in patients with primary epithelial ovarian cancer and germline BRCA1/2-mutation - real life data.

DOI: 10.1016/j.ygyno.2021.09.004

Year: 2021

Risk Reclassification of Patients with Endometrial Cancer Based on Tumor Molecular Profiling: First Real World Data

DOI: 10.3390/jpm11010048

Year: 2021

Ovarian cancer surgery

DOI: 10.1007/s12254-020-00596-y

Year: 2020

Basic Laparoscopic Skills Training Is Equally Effective Using 2D Compared to 3D Visualization: A Randomized Controlled Trial

DOI: 10.3390/jcm9051408

Year: 2020

Precision Medicine Tumor Boards: Clinical Applicability of Personalized Treatment Concepts in Ovarian Cancer

DOI: 10.3390/cancers12030548

Year: 2020

What are Broad Spectrum Antibiotics?

What are Minimal Side Effects?

What Role Does Professional Development Play?

What are Transfusion Transmitted Infections (TTIs)?

How is the Bishop Score Calculated?

Why is Laparoscopic Surgery Preferred?

What About Medical Treatments?

How Does Intermediate Acting Insulin Help in PCOS?

Why is Nutritional Assessment Important?

What is Menopause and How Does it Affect Health?

Partnered Content Networks

Relevant Topics